Friday, December 1st, 2023


A full text version of this article is available.
To access article obtain online access here or login
Liver Damage After Radiofrequency Ablation Combined with Transcatheter Therapy in Treating Rabbit VX2 Liver Tumors
Authors:  Xu-Hua Duan, M.D., Wen-Hui Wang, M.M., Xin-Wei Han, M.D., Jian-Zhuang Ren, M.D., Hao Li, M.M., Peng-Fei Chen, M.M., Shao-Jun Gong, M.M., and Dong-Lin Kuang, M.M.
  Objective: To evaluate the effect of transcatheter therapies combined with radiofrequency ablation (RFA) treatment on hepatocellular necrosis, apoptosis, and proliferation by using the rabbit VX2 tumor model.
Study Design:
Ninety-six models were randomly divided into 4 groups: transcatheter arterial chemoembolization (TACE) group, radiofrequency ablation group (RFA) group, TACE+RFA group, and transcatheter arterial embolization (TAE)+RFA group.
The high expression of heat shock protein 70 (HSP70) was observed in the adjacent liver tissue in TACE and TACE+RFA. The highest increase of transaminase levels and serum HSP70 were detected in the TACE+RFA group. The TAE+RFA group had a low apoptotic rate and more hepatocyte proliferation as compared to the TACE and TACE+RFA groups, and it had the longest end-point survival among these groups.
The TAE+RFA treatment had a better outcome than RFA, including better liver tumor control, less liver injury, and a longer survival. Compared to TACE and TACE+RFA procedures, TAE+RFA significantly decreased the liver injury, hepatocellular necrosis, apoptosis, and systemic proinflammatory cytokine release caused by anticancer drug application.
Keywords:  HSP70 heat-shock proteins, radiofrequency ablation, TACE, TAE, therapeutic chemoembolization, transcatheter arterial chemoembolization, transcatheter arterial embolization
  Acrobat Reader 7.0 is recommended to properly view and print the article.
Reader can be downloaded from